Sept. 23 Financial Quick Takes: Innate looks to add U.S. listing; plus Curamir's launch, Qihan Bio and Vedanta
Innate proposes U.S. listing
Innate Pharma S.A. (Euronext:IPH) filed to raise up to $100 million total across a NASDAQ listing and a European private placement. The antibody company markets CD22-targeted immunotoxin Lumoxiti moxetumomab in the U.S.; its pipeline includes three clinical cancer candidates and six preclinical oncology programs. Underwriters are Citigroup, SVB Leerink and Evercore.
Delos launches Watson's Curamir with $10M A round
Delos Capital launched micro RNA-based cancer therapeutics company Curamir Therapeutics Inc. with a $10 million series A. Curamir was co-founded by gene regulation veterans James Watson, a Nobel laureate; Jingfang Ju, a professor of pathology at Stony Brook University; and Lan Bo Chen, professor emeritus of pathology at Harvard Medical School and Academician of Academia Sinica of Taiwan...